Suppr超能文献

噻嗪类利尿剂作为严重肾病患者的慢性抗高血压治疗 - 在没有利尿作用的情况下是否有作用?

Thiazide diuretics as chronic antihypertensive therapy in patients with severe renal disease--is there a role in the absence of diuresis?

机构信息

School of Pharmacy, University of Southern California, Los Angeles, CA, USA.

出版信息

Ann Pharmacother. 2012 Nov;46(11):1554-8. doi: 10.1345/aph.1R212. Epub 2012 Nov 7.

Abstract

OBJECTIVE

To determine whether thiazides have a chronic antihypertensive effect, in the absence of diuresis, in patients with severe renal disease (creatinine clearance <30 mL/min) or in those receiving dialysis.

DATA SOURCES

A search was performed in PubMed, CENTRAL, and International Pharmaceutical Abstracts, using MeSH terms and/or key words. MeSH terms included kidney failure, chronic and exploded terms hydrochlorothiazide, renal dialysis, and thiazides. Key words included thiazide*, hydrochlorothiazide, chlorothiazide, chlorthalidone, indapamide, metolazone, methyclothiazide, bendroflumethiazide, hemodialysis, dialysis, kidney failure, renal failure, renal insufficiency, hypertension, vasodilation, vascular, and diuretics.

STUDY SELECTION AND DATA EXTRACTION

All relevant English-language publications were evaluated. Studies evaluating the efficacy of thiazides in renal insufficiency or dialysis were limited to those that included blood pressure measurements. Studies were included only if treatment duration was at least 4 weeks to evaluate chronic antihypertensive effects.

DATA SYNTHESIS

Thiazide diuretics are associated with a chronic reduction in peripheral vascular resistance secondary to a purported vasodilatory effect. However, few clinical studies have evaluated the chronic antihypertensive efficacy of thiazide and thiazide-like diuretics in patients with severe renal disease or those on dialysis. Agents studied include hydrochlorothiazide, chlorothiazide, indapamide, and metolazone, with results varying by drug and patient population. Hydrochlorothiazide 25-200 mg daily, chlorothiazide 500 mg twice daily, and indapamide 2.5 mg daily provided long-term blood pressure reduction in patients with severe renal disease who were not on dialysis. In studies involving patients on dialysis, hydrochlorothiazide 50 mg daily and metolazone 5 mg daily did not affect blood pressure; however, 1 study suggested that indapamide 2.5 mg daily may confer an antihypertensive effect. All studies were small (≤12 subjects) and had methodological limitations.

CONCLUSIONS

Thiazide diuretics may decrease peripheral vascular resistance independent of natriuresis. However, because current clinical data are inconclusive as to the efficacy of these agents at chronically lowering blood pressure in patients with severe renal disease or in those on dialysis, thiazide diuretics cannot be routinely recommended for this indication.

摘要

目的

确定噻嗪类药物在没有利尿作用的情况下,是否对严重肾功能障碍(肌酐清除率<30 mL/min)或透析患者具有慢性降压作用。

资料来源

在 PubMed、CENTRAL 和国际药学文摘中,使用 MeSH 术语和/或关键词进行了检索。MeSH 术语包括肾衰竭、慢性和扩展词氢氯噻嗪、肾透析和噻嗪类。关键词包括噻嗪*、氢氯噻嗪、氯噻嗪、氯噻酮、吲达帕胺、美托拉宗、甲氯噻嗪、苯氟噻嗪、血液透析、透析、肾衰竭、肾功能衰竭、肾功能不全、高血压、血管舒张、血管和利尿剂。

研究选择和资料提取

评估了所有相关的英文出版物。仅限于包括血压测量的研究,评估了噻嗪类药物在肾功能不全或透析中的疗效。只有当治疗时间至少为 4 周以评估慢性降压效果时,才纳入研究。

资料综合

噻嗪类利尿剂与外周血管阻力的慢性降低有关,这归因于所谓的血管舒张作用。然而,很少有临床研究评估噻嗪类和噻嗪类利尿剂在严重肾功能障碍或透析患者中的慢性降压疗效。研究的药物包括氢氯噻嗪、氯噻嗪、吲达帕胺和美托拉宗,结果因药物和患者人群而异。氢氯噻嗪 25-200 mg/d、氯噻嗪 500 mg 每日 2 次和吲达帕胺 2.5 mg/d 为未透析的严重肾功能障碍患者提供了长期的血压降低。在涉及透析患者的研究中,氢氯噻嗪 50 mg/d 和美托拉宗 5 mg/d 对血压没有影响;然而,1 项研究表明,吲达帕胺 2.5 mg/d 可能具有降压作用。所有研究的规模都较小(≤12 例)且存在方法学局限性。

结论

噻嗪类利尿剂可能会降低外周血管阻力,而不依赖于排钠作用。然而,由于目前的临床数据对于这些药物在严重肾功能障碍或透析患者中慢性降压的疗效尚无定论,因此不能常规推荐噻嗪类药物用于该适应证。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验